Alpha Tau Medical (DRTS) Investor presentation summary

Technology and therapeutic approach

• Alpha DaRT uses localized alpha particle radiotherapy to destroy solid tumors while sparing healthy tissue, leveraging the decay chain of Radium-224 for potent, short-range cytotoxic effects.

• Designed to overcome the limited range of alpha radiation by releasing alpha emitters deeper into tumors, achieving tight, effective radiation distribution.

• Demonstrates potential for both standalone use and synergy with other cancer treatments, including immunotherapies.

• Over 150 patents granted and more than 200 applications pending, supporting a robust intellectual property position.

Clinical development and milestones

• Multiple pivotal and pilot studies underway in the U.S. for recurrent cutaneous SCC, pancreatic cancer, and recurrent GBM, with key data readouts and regulatory submissions anticipated in 2026.

• Early clinical data in skin cancers show a 100% complete response rate in a pilot study, with mild or moderate adverse events and no serious treatment-related events.

• Pancreatic cancer trials report a 19% objective response rate and a 97% disease control rate (excluding feasibility patients), with ongoing survival analyses in key subpopulations.

• Combination trials with pembrolizumab in head and neck cancers show a 75% systemic objective response rate and 37.5% complete responses, with minimal adverse events.

Market opportunity and unmet need

• Targeting high unmet need indications: cutaneous and head & neck SCC, prostate, liver, breast, GBM, and pancreatic cancers.

• U.S. annual incidence: 1.8 million cSCC cases, ~54,000 HNSCC cases, and ~66,000 pancreatic cancer cases, with most patients ineligible for surgery.

• GBM represents a critical need, with average survival of 8 months and a 5-year survival rate below 7%.